Respiree, a health tech company developing artificial intelligence (AI) platforms to manage disease progression across the healthcare continuum, has announced the successful closing of an $11.6 million Series A financing round, led by We Venture Capital and ClavystBio, with participation from Adaptive Capital Partners also..

Respiree，一家开发人工智能（AI）平台以管理整个医疗保健过程中的疾病进展的健康科技公司，宣布成功完成了1160万美元的A轮融资，本轮融资由We Venture Capital和ClavystBio领投，Adaptive Capital Partners也参与其中。

Respiree’s innovative, augmented-AI platform seeks to support quicker, efficient, and precise decision making in various healthcare settings by automating patient monitoring, care pathway management, and clinical insight delivery. One of its flagship AI models developed during the Mayo Clinic Platform Accelerate programme, where Respiree graduated from, can help healthcare professionals detect patient deterioration earlier – including rapid response calls in general wards and unplanned ICU transfers..

Respiree的创新增强型人工智能平台旨在通过自动化患者监测、护理路径管理和临床洞察提供，支持各种医疗环境中的快速、高效和精准决策。其在梅奥诊所平台加速计划中开发的旗舰AI模型之一（Respiree从该计划毕业）可以帮助医疗专业人员更早发现患者的病情恶化——包括普通病房的快速响应呼叫和计划外的ICU转移。

Published as a pre-print in

作为预印本发布于

The Lancet

柳叶刀

, Respiree’s flagship AI model significantly reduced false alarms while maintaining strong sensitivity – outperforming the positive predictive value (PPV) of EPIC’s deterioration index by a factor of six (54.9% vs 8%).

，Respiree的旗舰AI模型在保持高度敏感性的同时显著减少了误报——其阳性预测值（PPV）超出EPIC的恶化指数六倍之多（54.9% 对 8%）。

Proceeds from the financing round will support expansion of Respiree’s commercial team and US presence, including company headquarters in Houston, Texas, at the Texas Medical Center (TMC) Innovation.

本轮融资的收益将用于支持 Respiree 商业团队的扩展及美国业务的发展，包括在德克萨斯州休斯顿的德州医疗中心 (TMC) 创新区设立公司总部。

Respiree is currently in the process of seeking clearance from the US Food and Drug Administration (FDA) for this flagship AI model, with the goal of integrating it into its platform, 1Bio, which already incorporates data from electronic health records (EHRs), mobile questionnaires, third party devices, and Respiree’s proprietary, US-patented, FDA-cleared sensors to provide longitudinal insights into disease trajectories..

Respiree目前正在寻求美国食品药品监督管理局（FDA）对其旗舰人工智能模型的批准，目标是将其整合到其平台1Bio中。该平台已经融合了来自电子健康记录（EHR）、移动问卷、第三方设备以及Respiree专有的、已获得美国专利和FDA批准的传感器的数据，以提供对疾病发展轨迹的纵向洞察。

Dr Gurpreet Singh, founder and CEO of Respiree, commented on the funding round: “The digitalisation of healthcare offers a powerful opportunity to improve outcomes and efficiency – but without the right tools, it risks overwhelming care systems, especially amid workforce shortages.”

Respiree创始人兼首席执行官古尔普雷特·辛格博士在谈到此轮融资时评论道：“医疗保健的数字化提供了改善结果和效率的强大机会——但如果没有合适的工具，它有可能压垮护理系统，尤其是在劳动力短缺的情况下。”

Singh added: “What we need is better use of data, not just more data. Our AI solutions enable timely interventions, reduce alarm fatigue, and support care quality. We're now focused on scaling these tools to enhance the entire patient journey – from smarter triage to follow-up.”

辛格补充道：“我们需要的是更好地利用数据，而不仅仅是更多的数据。我们的人工智能解决方案能够实现及时干预、减少警报疲劳并支持护理质量。我们现在正专注于扩展这些工具，以优化整个患者的诊疗过程——从更智能的分诊到后续跟进。”

Louise Warme, head of We Venture Capital, said: “We are very proud to welcome Respiree to the We VC portfolio. [It] stands out in the market by providing a patient monitoring AI/ML + hardware solution with incredible performance, but also unmatched understanding and execution of clinical workflow integration.”.

路易丝·瓦尔梅，We Venture Capital的负责人表示：“我们非常自豪地欢迎Respiree加入We VC的投资组合。它通过提供一款性能卓越的患者监测AI/ML+硬件解决方案在市场中脱颖而出，同时在临床工作流程整合方面也展现了无与伦比的理解和执行力。”

Meanwhile, Anselm Tan, ClavystBio’s digital health & medtech lead, commented: “ClavystBio’s investment in Respiree is central to our strategy of helping companies scale globally from and through Singapore. Their innovative AI-powered monitoring platform is set to enhance patient care and empower clinical teams with actionable insights.”.

同时，ClavystBio 的数字健康与医疗技术主管安塞尔姆·谭评论道：“ClavystBio 对 Respiree 的投资是我们通过新加坡帮助公司实现全球扩展的战略核心。他们创新的 AI 驱动监测平台将提升患者护理质量，并为临床团队提供可操作的洞察。”

Founded in Singapore,

成立于新加坡，

Respiree

呼吸器

is now executing its global strategy to expand into new markets worldwide. The company’s solutions are currently available in the US, Australia, and across Asia-Pacific (APAC), and Respiree recently announced a partnership with

目前正在执行其全球战略，以拓展至全球新市场。该公司的解决方案目前已在美国、澳大利亚以及亚太地区（APAC）上市，并且Respiree最近宣布与

Roche Diagnostics

罗氏诊断

to launch pilot programmes across the APAC region.

在亚太地区推出试点项目。

A portion of the Series A funds will be used to strengthen operations with existing channel partners and accelerate the development of new business relationships. Respiree plans to expand its offerings into newer international markets including the Gulf Cooperation Council and Thailand.

A轮融资的一部分将用于加强与现有渠道合作伙伴的运营，并加速新业务关系的开发。Respiree计划将其业务扩展到包括海湾合作委员会和泰国在内的新兴国际市场。